We conclude that high DNMT3B expression independently associates with adverse outcome in older CN-AML patients.

FLT3-ITD identifies older CN-AML patients with molecular high risk and is associated with gene- and microRNA-expression signatures that provide biologic insights for novel therapeutic approaches.